¿Tienen todos los carbapenems la misma capacidad convulsivante?

• Autores: Jaime E. Poquet Jornet, G. Morlà Clavero
• Localización: Atención Farmacéutica, ISSN 1139-7357, Vol. 6, Nº. 5, 2004, págs. 343-350
• Idioma: español
• Títulos paralelos:
  • Do all carbapenems have the same convulsant capacity?
• Texto completo no disponible (Saber más ...)
• Resumen

  • The family of carbapenems includes three antibiotics: imipenem, meropenem and ertapenem (recently commercialized). Their action mechanism makes them particularly efficient in infections produced by gram-positive, as well as gram-negative bacteria. These drugs' main problems, specially in the case of imipenem, are the side effects and specifically the seizures that may force a treatment suspension. The main risk factors for presenting seizures are: previous injuries in the CNS, epilepsy, renal insufficiency, excessive dosage, treatments of more than seven days in duration and the presence of infection by Pseudomonas aeruginosa